Drug intelligence / Profile preview

IDX19368

Development stage: Discontinued
Lead developer: Merck
Modality: Small Molecules
Administration: Oral

Overview

IDX19368 is a next-generation guanosine-based nucleotide prodrug and **NS5B polymerase inhibitor** developed by Idenix Pharmaceuticals for the treatment of **hepatitis C virus (HCV)** infection. It demonstrated strong potency in preclinical studies against HCV but never advanced to human clinical trials due to an FDA-imposed clinical hold in August 2012 related to cardiac adverse events observed with related compounds, followed by voluntary discontinuation of the program in February 2013.[1][2][5][10][11]

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)POLRMT (Mitochondrial RNA polymerase)

Beyond the preview

Go deeper on IDX19368.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDX19368.

Explore the full profile